INHIBITING GLYCO-IMMUNE CHECKPOINTS

Targeting glycan-sensing checkpoints to unleash both innate and adaptive immune response to cancer

Developing novel, first-in-class medicines to transform the treatment of cancer

We are driven to advance a completely new modality for cancer